Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
US10918665B2 · kind B2 · utility
6Cited by
9References
57Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 5, 2017 |
| Grant date | Feb 16, 2021 |
| Priority date | — |
| Expiry date | May 27, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/203
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.